1:Why do research sponsors be concerned about potential FCPA violations when they conduct clinical trials outside the U.S.? 2:What does the government need to prove to establish a violation of the FCPA's anti-bribery provisions?

What does the government need to prove to establish a violation of the books and records provisions? 3:What is the "routine government payment" exception to the FCPA? When could a research sponsor rely on this exception, if ever? 4:How does the UK Bribery Act differ from the FCPA?

Why have commentators argued that the Russian anti-bribery law is even stricter than the UK Bribery Act?